ZOM Zomedica Pharmaceuticals Corp

$0.21 $0.00 (-0.47%)
Overall

ZOM Stock Analysis Overview

What this means: InvestorsObserver gives Zomedica Pharmaceuticals Corp (ZOM) an overall rank of 42, which is below average. Zomedica Pharmaceuticals Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 42 means that 58% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ZOM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ZOM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ZOM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ZOM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ZOM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ZOM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ZOM Stock Analysis Overview

What this means: InvestorsObserver gives Zomedica Pharmaceuticals Corp (ZOM) an overall rank of 42, which is below average. Zomedica Pharmaceuticals Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 42 means that 58% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ZOM report

ZOM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ZOM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ZOM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ZOM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ZOM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ZOM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Zomedica Pharmaceuticals Corp (ZOM) Analyst Forecast

ZOM Price, Volume, Earnings, and Dividend Date

  • Last Price $0.21
  • Previous Close $0.21
  • Change $0.00
  • Open $0.21
  • Volume 5,742,951
  • Avg. Volume (100-day) 19,010,956
  • Market Cap 206,769,380
  • Days Range 0.211 - 0.2249
  • 52-week Range 0.17 - 0.63
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date 11/11/22
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec. Premium
  • Beta 1.164
  • PEG Ratio

Zomedica Pharmaceuticals Corp (ZOM) Company Description

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.

Zomedica Pharmaceuticals Corp (ZOM) Stock Chart

My Watchlists

Follow Your Favorite Stocks